Impact of HIV kick-and-kill therapy on host epigenetic and transcriptional programs in PBMC, and viral rebound after cART interruption

Background: BCN02 was a pilot kick-and-kill clinical trial that combined therapeutic vaccination (MVA.HIVconsv) with the latency reversing agent romidepsin (RMD) followed by a monitored antiretroviral pause (MAP) in 15 early-treated HIV+ individuals (NCT02616874). Out of 12 evaluable participants fo...

Full description

Authors: Oriol-Tordera, Bruna; Esteve-Codina, Anna; Berdasco, María; Gonçalves, Elena; Esteller, Manel; Hanke, Tomá; Moltó, José; Clotet, Bonaventura, 1953-; Calle, María Luz; Combadiere, Behazine; Sànchez, Àlex (Sànchez Pla); Mothe, Beatriz; Ruiz-Riol, Marta; Brander, Christian
Format: Article
Status:Published version
Publication date:2021
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/198070
Online Access:https://hdl.handle.net/2445/198070
Access Level:Open access
Keyword:VIH (Virus)
Epigenètica
HIV (Viruses)
Epigenetics
Summary:Background: BCN02 was a pilot kick-and-kill clinical trial that combined therapeutic vaccination (MVA.HIVconsv) with the latency reversing agent romidepsin (RMD) followed by a monitored antiretroviral pause (MAP) in 15 early-treated HIV+ individuals (NCT02616874). Out of 12 evaluable participants for an omics subanalysis, 8 participants showed early (pVL > 2000 copies/mL < 4 weeks) and 4 a more delayed viral rebound (pVL > 2000 copies/mL > 4 weeks) in MAP. Systems biology analyses identified epigenetic and molecular mechanisms associated with response to vaccination and RMD and viral rebound kinetics.

Similar Items